https://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.png00Lauren Fishhttps://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.pngLauren Fish2019-04-12 05:48:132019-04-12 05:48:13Amplyx Pharmaceuticals Announces Presentations at the 29th ECCMID in Amsterdam
https://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.png00jcalhoonhttps://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.pngjcalhoon2019-02-11 06:12:262019-02-11 06:12:26FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
https://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.png00jcalhoonhttps://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.pngjcalhoon2019-01-31 15:12:552019-01-31 15:12:55Antimicrobials Working Group Announces Updates to Leadership Team
https://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.png00jcalhoonhttps://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.pngjcalhoon2018-11-12 16:35:132018-11-12 16:35:13Amplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection
https://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.png00jcalhoonhttps://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.pngjcalhoon2018-06-07 05:00:222018-06-07 14:00:34Amplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host
https://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.png00jnellishttps://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.pngjnellis2018-06-05 05:12:532018-06-05 05:14:21Amplyx Pharmaceuticals to Participate in BIO International Convention Panel and Present at Jefferies Global Healthcare Conference
https://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.png00jnellishttps://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.pngjnellis2018-04-30 11:33:562018-10-23 10:17:31Amplyx Pharmaceuticals Demonstrates APX001 has Potent Activity Against Deadly Multidrug-Resistant Candida Species
https://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.png00adminhttps://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.pngadmin2018-03-19 08:45:312018-03-19 08:48:24Amplyx Pharmaceuticals Receives Fourth "Qualified Infectious Disease Product" (QIDP) Designation from the FDA for APX001
https://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.png00adminhttps://amplyx.com/wp-content/uploads/AmplyxKnockout_RGB-350x201.pngadmin2018-01-08 05:06:192018-01-08 05:06:19Amplyx Pharmaceuticals Announces Appointment of CFO and Presentation at the J.P. Morgan 36th Annual Healthcare Conference
